Current Bioinformatics Seminar
28 February 2017
Backstory and promising first steps in a study of relapse in Core-Binding Factor Acute Myeloid LeukemiaAnna Quaglieri
Core Binding Factor Acute Myeloid Leukemia (CBF-AML) is a type of Leukemia characterised by two well known recurrent genomic rearrangements. Even though CBF-AML patients have overall a more favourable outcome than patients with other type of leukemia, the proportion of relapse is still around 40%. Here, we present the initial phase of our research that will lead to a better understanding of the mechanism behind relapse. As part of a clinical trial led by the Australasian Leukemia and Lymphoma group, RNA-Seq was performed on patients at Diagnosis, Remission and Relapse. The sequencing design was informed by the analysis of previously published CBF-AML data. Preliminary analyses of the gene counts and fusions show encouraging patterns associated with disease progression and the subtypes of CBF-AML.